In the Margins
French pharmaceutical company Sanofi said it will seek to replace the board of Medivation after the American drug maker’s directors rejected a $9.3 billion takeover offer. Sanofi said in April that Medivation’s directors had failed to respond to its approach. Meanwhile, Medivation’s board called the offer “inadequate,” and founder and CEO David Hung has said the French company’s move was “opportunistically timed.” Read the original story from The New York Times.
Most Read
Resignations, retirements and recruitment over the past five years have led to significant changes in the Sequoia Fund boardroom. The transformation was set in motion in ...
New data from Independent Directors Council suggests that most independent mutual fund directors did not see much of a bump in compensation in 2019, with year-on-year ...
When new members join and long-serving members leave a mutual fund board, it can be difficult to maintain a carefully honed boardroom culture. At Hartford Funds, ...
Mutual funds claiming to invest in accordance with environmental, social, and governance (ESG) principles are not short of attention of late. There is a wide variety ...